Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0JFGYQ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
caxmotabart entudotin
|
|||||
| Synonyms |
LCB14-0110; FS-1502; IKS014; LCB-ADC
Click to Show/Hide
|
|||||
| Organization |
LCB (Originator);Fosun Pharma;Iksuda Therapeutics
|
|||||
| Drug Status |
Phase 3
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2 ECD2); Receptor tyrosine-protein kinase erbB-2 (HER2 ECD4)
|
Antigen Info | ||||
| Payload Name |
MMAF
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
β-glucuronide linker
|
Linker Info | ||||
| Conjugate Type |
Enzymatic Catalysis
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Breast cancer |
2 Trials
|
1 Trials
|
||||||||||
| Colorectal cancer |
1 Trials
|
|||||||||||
| Gastric cancer |
1 Trials
|
1 Trials
|
||||||||||
| Gastroesophageal junction adenocarcinoma |
1 Trials
|
1 Trials
|
||||||||||
| Lung cancer |
1 Trials
|
|||||||||||
| Unspecific solid tumor |
2 Trials
|
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
66.70
42.90 % |
|||
| Patients Enrolled |
Patients with HER2-expresssing advanced solid tumors who had failed prior standard of care therapies.
|
||||
| Administration Dosage |
FS-1502 was given IV once in 21-day or 28-day cycle at doses of 0.10-3.50 mg/kg.
|
||||
References